|
In dirittura d’arrivo molte nuove molecole
Corriere della Sera È un anticorpo monoclonale anche ocrelizumab (Roche), al momento in fase 3 della sperimentazione: le procedure di registrazione dovrebbero arrivare nel 2015, quando è atteso anche l’arrivo di daclizumab HYP (anticorpo monoclonale in formulazione … |
Searching for the next new blockbuster drug treatmentWorcester TelegramAnother biological drug called Daclizumab, under development with Weston-based Biogen Idec as a treatment for multiple sclerosis, is in the third and final phase of human studies. S…
The Best Big Biotech for 2013DailyFinanceResults from a phase 3 study of daclizumab HYP, another multiple sclerosis drug developed in partnership with AbbVie , are expected in 2014. Celgene Celgene provided upbeat product and financial updates. CEO Bob…
The Best Big Biotech for 2013Motley FoolThe company also anticipates phase 3 results for PEG Interferon Beta-1A in the first half of this year. Results from a phase 3 study of daclizumab HYP, another multiple sclerosis drug developed in partnership wit…
|
Research and Markets: Biogen-Idec’s and Facet Biotech’s Daclizumab: Can It …
PharmiWeb.com (press release) Daclizumab is the active agent in Zenapax (Roche), a humanized antibody that blocks the IL-2 receptor. It was first approved in 1997 for transplant rejection prevention. A phase II study in multiple sclerosis (MS) showed evidence of activity and an … |
|
Research and Markets: Biogen-Idec’s and Facet Biotech’s Daclizumab: Can It …
Fort Mills Times Daclizumab is the active agent in Zenapax (Roche), a humanized antibody that blocks the IL-2 receptor. It was first approved in 1997 for transplant rejection prevention. A phase II study in multiple sclerosis (MS) showed evidence of activity and an … |
|
AbbVie’s Born — What Now?
Motley Fool Multiple sclerosis treatment daclizumab, a partnership project with Biogen Idec (NASDAQ: BIIB ) , should report data sometime next year. Brian Orelli discussed the mid-stage trial results containing promising efficacy better than Teva’s (NYSE: TEVA ) … |
AbbVie targets 2015 growth with focus on new specialty drugsChicago Daily HeraldAbbVie also is developing daclizumab, a treatment for multiple sclerosis in the late stage of clinical trials that may reach the market by late 2015 or early 2016. Finally,…
AbbVie targets 2015 growth with focus on new specialty drugsWorcester TelegramAbbVie also is developing daclizumab, a treatment for multiple sclerosis in the late stage of clinical trials that may reach the market by late 2015 or early 2016. Finally, t…
AbbVie Plans Specialty Drug Focus in Sales Growth EffortBloombergAbbVie also is developing daclizumab, a treatment for multiple sclerosis in the late stage of clinical trials that may reach the market by late 2015 or early 2016. Finally, the company ha…